Akari Therapeutics (AKTX) releases updated investor presentation for meetings

Rhea-AI Filing Summary

Akari Therapeutics, Plc reported that it has prepared a new investor presentation dated December 8, 2025. Company officers and representatives intend to use this presentation at conferences and meetings to explain Akari’s business and prospects to current and potential investors.

The materials are provided as an exhibit to this report and are classified as “furnished” rather than “filed,” meaning they are not subject to certain liability provisions of the U.S. securities laws and are not automatically incorporated into other company filings.

false 0001541157 0001541157 2025-12-08 2025-12-08 0001541157 AKTX:AmericanDepositarySharesEachRepresenting2000OrdinarySharesMember 2025-12-08 2025-12-08 0001541157 AKTX:OrdinarySharesParValue0.0001PerShareMember 2025-12-08 2025-12-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 8, 2025

Akari Therapeutics, Plc

(Exact name of Registrant as Specified in Its Charter)

England and Wales		001-36288		98-1034922
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

401 East Jackson Street, Suite 3300 Tampa, FL		33602
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (929) 274-7510

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
American Depositary Shares, each representing 2000 Ordinary Shares		AKTX		The Nasdaq Stock Market LLC
Ordinary Shares, par value $0.0001 per share*		N/A		The Nasdaq Stock Market LLC

*Trading, but only in connection with the American Depositary Shares.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On December 8, 2025, Akari Therapeutics, Plc (the “Company”) prepared an investor presentation that officers and other representatives of the Company intend to present at conferences and meetings. A copy of the investor presentation is furnished as Exhibit 99.1 of this Current Report on Form 8-K.

The information set forth in this Item 7.01 of this Current Report on Form 8-K and in the attached Exhibit 99.1 are deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information set forth in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Investor Presentation.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Akari Therapeutics, Plc
Date:	December 8, 2025	By:	/s/ Abizer Gaslightwala
		Name:	Abizer Gaslightwala
		Title:	President and Chief Executive Officer

FAQ

What did Akari Therapeutics (AKTX) announce in this report?

Akari Therapeutics, Plc announced that it prepared a new investor presentation dated December 8, 2025, to be used by its officers and representatives at conferences and meetings.

How is the Akari Therapeutics (AKTX) investor presentation provided to the public?

The investor presentation is included as Exhibit 99.1 to this report, allowing investors and analysts to review the same materials used in conferences and meetings.

Is the Akari Therapeutics (AKTX) investor presentation considered filed with the SEC?

The company states that the information in Item 7.01 and Exhibit 99.1 is deemed “furnished” and not “filed,” so it is not subject to certain liability provisions of Section 18 of the Exchange Act.

Does this Akari Therapeutics (AKTX) disclosure automatically update other SEC filings?

No. Akari specifies that the information in Item 7.01 and Exhibit 99.1 is not incorporated by reference into any other filing under the Exchange Act or the Securities Act, despite any general incorporation language elsewhere.

Who signed this Akari Therapeutics (AKTX) report?

The report was signed on behalf of Akari Therapeutics, Plc by Abizer Gaslightwala, the company’s President and Chief Executive Officer.